<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="58793" end="58798" sStart="58549" offset="244" sid="r7.1.use.v.0502" wn="1" wnkey="use%2:34:01::" text="Briefly, approximately 10 8cells were transfected with pcDNA 3.1 constructs (Invitrogen) bearing either murine Smo (wild-type or W539L mutant), GFP, rat ?2AR (Invitrogen), or murine Ptc cDNAs using Fugene 6 (Roche)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1475-4924-1-10.anc" start="61167" end="61178" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" text="2 ml for association/dissociation studies and 0.75 ml in saturation and competition experiments) were then &lt;b&gt;transferred&lt;/b&gt; to the pre-coated 96-well filtration plates (Millipore fiberglass FB filters), filtered and washed over a vacuum manifold with six 300 ?l per well washes of binding buffer supplemented with 2% hydoxypropyl cyclodextrin (HPCD; Sigma; ST Louis, USA) + 0.1% BSA to decrease non-specific binding." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="40109" end="40116" sStart="null" offset="23" sid="r8.suggest.v.0213" wn="3" wnkey="suggest%2:32:02::" text="Specifically, our data suggest that the agonist binds and stabilizes (or induces) an active signaling state of Smo while the antagonists bind and stabilize (or induce) an inactive form." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="59995" end="60004" sStart="null" offset="292" sid="r8.suggest.v.0140" wn="1" wnkey="suggest%2:32:00::" text="Using these membranes, filtration binding assays were performed according to previously described protocols [ 28 ] . To reduce nonspecific binding, 96-well filtration plates (fiberglass FB filters; Millipore, Bedford, USA) were pre-coated as suggested by the manufacturer with 0.5% polyethyleneimine + 0.1% BSA and then washed four times with 0.1% BSA." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="38814" end="38822" sStart="null" offset="310" sid="r8.suggest.v.0955" wn="3" wnkey="suggest%2:32:02::" text="Thus we introduce a ternary complex model (Figure 8b), used traditionally to describe the behavior of GPCRs in binding studies with agonist and antagonists [ 31 ] , as well as constitutively active receptors [ 29 ] . The ternary complex model for Hh signaling suggests that there are two independent binding sites on Smo wt, one specific for the agonist and another specific for antagonists." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1475-4924-1-10.anc" start="18943" end="18949" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" text="Furthermore, this supports the data &lt;b&gt;showing&lt;/b&gt; that the agonist can activate signaling in Shh -/-embryos (Figure 3) and suggests that the agonist function is not only downstream of the Hh protein but also independent of the endogenous Hh-signaling modulators, Tout veloux and HIP, that act via the Hh ligand [ 2 ] . The competition experiment with forskolin &lt;b&gt;showed&lt;/b&gt; identical inhibition curves for Hh protein and the agonist, strongly suggesting that the action of the small molecule is upstream of the protein-kinase-A-sensitive step in the pathway." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="8226" end="8234" sStart="null" offset="253" sid="r11.refer.v.0517" wn="7" wnkey="refer%2:32:04::" text="We then introduced into each line a plasmid containing a luciferase reporter downstream of multimerized Gli binding sites and a minimal promoter [ 20 ] . An isolated stable clone of the 10T1/2 cell transfectants (referred to as clone S12) gave a 10-20-fold up-regulation of luciferase activity (Figure 1a) when stimulated with Hh protein [ 21 ] for 24 hours." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="2362" end="2372" sStart="null" offset="221" sid="r10.particular.j.0741" wn="2147483647" wnkey="null" text="Given the role that Hh signaling plays in promoting progenitor-cell proliferation, it is not surprising that misregulation of Hh signaling has been implicated in the biology of certain cancers, in particular basal cell carcinoma (BCC) and medulloblastoma." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="4157" end="4167" sStart="null" offset="3" sid="r10.particular.j.0343" wn="2147483647" wnkey="null" text="In particular, little is known about the means by which Ptc exerts its inhibitory effect on Smo, or how Smo communicates with the cytoplasmic Ci/Gli transcription factor complex." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="56795" end="56801" sStart="null" offset="10" sid="r8.number.n.0355" wn="1" wnkey="number%1:07:00::" text="2 and the number of immunoreactive cells per explant counted." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="37766" end="37772" sStart="null" offset="276" sid="null" wn="2" wnkey="normal%3:00:02::" text="To interpret the results of the competition binding studies, we assume that the mutation in Smo act, like those in constitutively activate mutants of other GPCRs [ 29 ] , indirectly influences ligand binding by creating a change in the normal equilibrium between the different conformations of Smo." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="41795" end="41801" sStart="null" offset="555" sid="r9.normal.j.0593" wn="1" wnkey="normal%3:00:01::" text="Briefly, if this model is applied to Hh signaling, it proposes that, firstly, agonist and antagonists act at independent sites to select active and inactive conformations of Smo; secondly, that Smo engages an undefined coupler/effector, when it is in its signaling state; and finally, that the gain-of-function mutant form of Smo, Smo act, adopts an abnormal conformation that resembles the coupler/effector-bound signaling state of Smo with low affinity for antagonists but normal affinity for the agonist." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="37766" end="37772" sStart="null" offset="276" sid="null" wn="1" wnkey="normal%3:00:01::" text="To interpret the results of the competition binding studies, we assume that the mutation in Smo act, like those in constitutively activate mutants of other GPCRs [ 29 ] , indirectly influences ligand binding by creating a change in the normal equilibrium between the different conformations of Smo." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="37766" end="37772" sStart="null" offset="276" sid="null" wn="3" wnkey="normal%3:00:03::" text="To interpret the results of the competition binding studies, we assume that the mutation in Smo act, like those in constitutively activate mutants of other GPCRs [ 29 ] , indirectly influences ligand binding by creating a change in the normal equilibrium between the different conformations of Smo." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="37766" end="37772" sStart="null" offset="276" sid="null" wn="1" wnkey="normal%3:00:01::" text="To interpret the results of the competition binding studies, we assume that the mutation in Smo act, like those in constitutively activate mutants of other GPCRs [ 29 ] , indirectly influences ligand binding by creating a change in the normal equilibrium between the different conformations of Smo." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="37766" end="37772" sStart="null" offset="276" sid="null" wn="3" wnkey="normal%3:00:03::" text="To interpret the results of the competition binding studies, we assume that the mutation in Smo act, like those in constitutively activate mutants of other GPCRs [ 29 ] , indirectly influences ligand binding by creating a change in the normal equilibrium between the different conformations of Smo." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1475-4924-1-10.anc" start="49415" end="49421" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Various studies in mammals have shown that Hh genes are expressed in discrete areas of the adult organism and may function in the normal maintenance of &lt;b&gt;mature&lt;/b&gt; organ systems [ 43 44 45 46 ] . In addition, the regenerative healing of vascular and skeletal tissues following acute injuries appears to be aided by re-activating the Hh-signaling cascade [ 47 48 ] . Taken together, these observations suggest that the Hh pathway may represent a point of intervention for treating certain degenerative disorders." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1475-4924-1-10.anc" start="49415" end="49421" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Various studies in mammals have shown that Hh genes are expressed in discrete areas of the adult organism and may function in the normal maintenance of &lt;b&gt;mature&lt;/b&gt; organ systems [ 43 44 45 46 ] . In addition, the regenerative healing of vascular and skeletal tissues following acute injuries appears to be aided by re-activating the Hh-signaling cascade [ 47 48 ] . Taken together, these observations suggest that the Hh pathway may represent a point of intervention for treating certain degenerative disorders." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="27331" end="27337" sStart="null" offset="118" sid="r8.live.v.0163" wn="2147483645" wnkey="null" text="This result demonstrates that a Hh-agonist derivative can be covalently crosslinked to Smo in living cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="3008" end="3013" sStart="null" offset="217" sid="r9.level.n.0875" wn="1" wnkey="level%1:07:00::" text="Additional pathway components are thought to modulate the activity or subcellular distribution of these molecules [ 2 ] . There is positive and negative feedback at the transcriptional level as the Gli1 and Ptc1 genes are direct transcriptional targets of activation of the pathway." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="19976" end="19981" sStart="null" offset="197" sid="r9.level.n.0511" wn="1" wnkey="level%1:07:00::" text="These results argue that the agonist activates the pathway downstream of the Hh-Ptc interaction while cyclopamine, Cur61414 and the agonist may act at a similar level in the Hh-signaling cascade." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="46887" end="46895" sStart="null" offset="35" sid="r11.function.n.0903" wn="2" wnkey="function%1:07:00::" text="Thus, in considering models of Ptc function based on Hh-stimulated effects it is important to consider whether the form of Smo that is being observed is the active (coupler/effector bound) signaling state, or perhaps a downregulated and inactive form." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="23006" end="23010" sStart="null" offset="63" sid="r9.full.j.0137" wn="2" wnkey="full%5:00:01:whole:00" text="Yet the agonist is fully capable of activating the full signaling pathway." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="28913" end="28917" sStart="null" offset="137" sid="r9.fold.v.0036" wn="2147483646" wnkey="null" text="To control for this observation, we added an unlabeled, inactive Hh agonist to the binding assay at 2 ?M (a 1000-fold molar excess)." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="8275" end="8279" sStart="null" offset="302" sid="r9.fold.v.0951" wn="2147483645" wnkey="null" text="We then introduced into each line a plasmid containing a luciferase reporter downstream of multimerized Gli binding sites and a minimal promoter [ 20 ] . An isolated stable clone of the 10T1/2 cell transfectants (referred to as clone S12) gave a 10-20-fold up-regulation of luciferase activity (Figure 1a) when stimulated with Hh protein [ 21 ] for 24 hours." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="28913" end="28917" sStart="null" offset="137" sid="r9.fold.v.0036" wn="2147483646" wnkey="null" text="To control for this observation, we added an unlabeled, inactive Hh agonist to the binding assay at 2 ?M (a 1000-fold molar excess)." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="28913" end="28917" sStart="null" offset="137" sid="r9.fold.v.0036" wn="2147483645" wnkey="null" text="To control for this observation, we added an unlabeled, inactive Hh agonist to the binding assay at 2 ?M (a 1000-fold molar excess)." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="28913" end="28917" sStart="null" offset="137" sid="r9.fold.v.0036" wn="" wnkey="null" text="To control for this observation, we added an unlabeled, inactive Hh agonist to the binding assay at 2 ?M (a 1000-fold molar excess)." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="18003" end="18009" sStart="null" offset="593" sid="r8.family.n.0203" wn="3" wnkey="family%1:14:04::" text="These include: a Hh-protein-blocking antibody, 5E1 [ 23 ] ; a natural product derivative, cyclopamine [ 9 10 ] that has recently been shown to act downstream of Ptc, perhaps at the level of Smo [ 11 ] ; a recently identified synthetic small-molecule inhibitor, Cur61414, which has inhibitory properties similar to cyclopamine [ 17 ] ; and forskolin, an adenylate cyclase/protein kinase A activator that is thought to block Hh signaling by stimulating degradation of members of the Gli family of transcriptional activators [ 2 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="29826" end="29833" sStart="null" offset="303" sid="r10.control.n.0249" wn="4" wnkey="control%1:09:02::" text="Binding was assayed in the presence of KAAD-cyclopamine at 10 ?M (Figure 6c, column 4), tomatadine at 10 ?M (Figure 6c; Antag control 1, column 5), Cur61414 at 10 ?M (Figure 6c, column 6), or the inactive Cur61414 derivative (Figure 6c; Antag control 2, column 7) at 10 ?M." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="23836" end="23843" sStart="null" offset="35" sid="r10.control.n.0602" wn="4" wnkey="control%1:09:02::" text="Immunocomplexes from untransfected control and ?-adrenergic-receptor transfected cells did not contain significant counts (Figure 6a, columns 1, 2)." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="19441" end="19448" sStart="null" offset="38" sid="r9.appear.v.0370" wn="1" wnkey="appear%2:39:00::" text="Specifically, the agonist appears somewhat resistant to the inhibitory effect of cyclopamine and Cur61414." />
    <s path="[OANC]/data/written_2/technical/biomed/1475-4924-1-10.anc" start="28419" end="28426" sStart="null" offset="153" sid="r11.absence.n.0286" wn="1" wnkey="absence%1:26:00::" text="The Smo-containing membranes (column 1) are the only samples that exhibit significant binding above that seen in the absence of membranes." />
  </sentences>
</list>